间充质干细胞治疗缺血性脑卒中的临床前研究进展  

Preclinical research progress of mesenchymal stem cell therapy of for ischemic stroke

作　　者：张君[1] 姜夕锋 张帆[1] 田书娟 李全海[4] 闫宝勇 ZHANG Jun;JIANG Xi-feng;ZHANG Fan;TIAN Shu-juan;LI Quan-hai;YAN Bao-yong

机构地区：[1]河北医科大学第一医院干细胞再生医学临床研究中心,石家庄050000 [2]河北医科大学第一医院神经内科,石家庄050000 [3]河北贝特赛奥生物科技有限公司,石家庄050090 [4]河北医科大学医学与健康研究院,石家庄050017 [5]河北医科大学第一临床医学院,石家庄050017

出　　处：《中国医药生物技术》2024年第6期526-532,共7页Chinese Medicinal Biotechnology

基　　金：河北省重点研发计划生物医药创新专项(21372409D)。

摘　　要：缺血性脑卒中是一种临床发病率较高的脑血管疾病,是世界上导致死亡和永久性残疾的主要原因之一。目前其急性期溶栓治疗及神经保护措施常受到狭窄治疗时间窗的限制,加之出血并发症,使大多数患者错失最佳溶栓治疗时机,预后较差,缺乏理想治疗手段。间充质干细胞移植疗法是一种治疗缺血性脑卒中的新模式,由于其具有来源丰富、多向分化潜能、免疫原性低、旁分泌作用等优点而备受关注。已在动物实验中证实,间充质干细胞移植可以缓解神经系统缺陷,发挥神经损伤修复再生的作用,且安全可行,为缺血性脑卒中的治疗带来希望。然而,间充质干细胞移植的时间和最佳剂量是其临床应用的主要挑战。本文对间充质干细胞的生物学活性,间充质干细胞移植治疗缺血性脑卒中动物模型的给药途径、时间窗、剂量、有效性、分子机制及安全性等临床前研究进行综述,并讨论了间充质干细胞移植治疗在临床前研究的局限性,以期为间充质干细胞移植的临床转化研究提供理论依据。Ischemic stroke is a cerebrovascular disease with high clinical incidence rate,making it one of the main causes of death and permanent disability worldwide.Currently,acute phase thrombolytic therapy and neuroprotective measures are often limited by narrow treatment time windows and bleeding complications,leading to many patients missing the optimal opportunity for thrombolytic therapy and resulting in poor prognosis and a lack of ideal treatment methods.Mesenchymal stem cell transplantation therapy is a new approach for treating ischemic stroke that has garnered significant attention due to its advantages,such as abundant sources,multi-directional differentiation potential,low immunogenicity,and paracrine effects.Animal experiments have confirmed that mesenchymal stem cell transplantation can alleviate neurological defects,promote nerve damage repair and regeneration,and is safe and feasible,offering hope for the treatment of ischemic stroke.However,determining the optimal timing and dosage of mesenchymal stem cell transplantation remains a major challenge for its clinical application.This article provides a review of preclinical studies on the biological activity of mesenchymal stem cells,as well as the administration routes,time windows,doses,efficacy,molecular mechanisms,and safety of mesenchymal stem cell transplantation for the treatment of ischemic stroke in animal models.In addition,the limitations of preclinical studies on mesenchymal stem cell transplantation therapy are discussed with the aim of providing a theoretical basis for the clinical translational research of mesenchymal stem cell transplantation.

关 键 词：间充质干细胞 脑梗死 干细胞移植 临床前研究 再生医学 

分 类 号：R743.3[医药卫生—神经病学与精神病学]